FAS
Fatty Acid Synthase (FAS) is a multifunctional homodimeric enzyme protein, and it is the major enzyme required for the anabolic conversion of dietary carbohydrates to fatty acids. Fatty acid synthase catalyzes the conversion of acetyl-CoA and malonyl-CoA, in the presence of NADPH, into long-chain saturated fatty acids.
Human fatty acid synthase is a large homodimeric multifunctional enzyme that synthesizes palmitic acid. The unique carboxyl terminal thioesterase domain of fatty acid synthase hydrolyzes the growing fatty acid chain and plays a critical role in regulating the chain length of fatty acid released. Also, the up-regulation of human fatty acid synthase in a variety of cancer makes the thioesterase a candidate target for therapeutic treatment.
Fatty acid synthase of animal tissues is a complex multifunctional enzyme consisting of two identical monomers.
Products for FAS
- Cat.No. Product Name Information
-
GC15572
(+)-trans-C75
(2R,3S)-C75
enantiomer of C75, a fatty acid synthase (FAS) inhibitor -
GC16184
(-)-trans-C75
(2S,3R)-C75
enantiomer of C75, a FAS inhibitor -
GN10632
Betulin
(+)-Betulin, NSC 4644, Trochol
-
GC34065
C75
C75 is a specific inhibitor of fatty acid synthase (FASN/FAS) with moderate inhibitory activity, showing an IC50 value of 15.53 μM.
-
GC14025
Cerulenin
Helicocerin, NSC 116069
fatty acid synthase (FAS) inhibitor
-
GC38221
Desoxyrhaponticin
Desoxyrhaponticin is a stilbene glycoside from the Tibetan nutritional food Rheum tanguticum Maxim. Desoxyrhaponticin is a Fatty acid synthase (FASN) inhibitor, and has apoptotic effect on human cancer cells.
-
GC38535
Dihydrocurcumin
-
GC31406
FAS-IN-1
FAS-IN-1 is a potent inhibitor of fatty acid synthase (FASN) with an IC50 of 10 nM (WO2012064642A1, compound 29).
-
GC34311
FAS-IN-1 Tosylate
-
GC33398
FASN inhibitor 1
FASN inhibitor 1 is a fatty acid synthase (FASN) inhibitor extracted from patent US20170119786A1, compound 242A.
-
GC34584
FASN-IN-1
FASN-IN-1 is a fatty acid synthase (FASN) inhibitor extracted from patent WO2015134790A1, compound 56.
-
GC36030
FASN-IN-2
Denifanstat; TVB-2640; ASC-40
FASN-IN-2 (TVB-2640) is an orally active and potent Fatty Acid Synthase (FASN) inhibitor with an IC50 of 0.052 μM and an EC50 of 0.072 μM. -
GC36031
Fatostatin
125B11
Fatostatin (125B11) is a specific inhibitor of sterol regulatory element-binding proteins (SREBP) activation, inhibiting the activation of both SREBP-1 and SREBP-2. -
GC18121
Fatostatin A hydrobromide
Fatostatin (125B11) HBr
Fatostatin A hydrobromide (125B11 hydrobromide), a specific inhibitor of SREBP activation, impairs the activation of SREBP-1 and SREBP-2. Fatostatin A hydrobromide binds to SCAP (SREBP cleavage-activating protein), and inhibits the ER-Golgi translocation of SREBPs. Fatostatin A hydrobromide decreases the transcription of lipogenic genes in cells. Fatostatin A hydrobromide possesses antitumor properties, and lowers hyperglycemia in ob/ob mice. -
GC31323
FGH10019
FGH10019 is a novel sterol regulatory element-binding protein (SREBP) inhibitor with IC50 of 1 μM.
-
GC33374
HS79
HS-79 is an enantiomer of Fasnall, which is a selective fatty acid synthase (FASN) inhibitor. HS-79 is able to inhibit the incorporation of tritiated acetate into lipids with an IC50 of 1.57 μM.
-
GC33346
HS80
HS-80 is an enantiomer of Fasnall, which is a selective fatty acid synthase (FASN) inhibitor. HS-80 is able to inhibit the incorporation of tritiated acetate into lipids with an IC50 of 7.13 μM.
-
GC14316
ML-356
thioesterase domain of fatty acid synthase (FAS-TE) inhibitor
-
GC36736
Nicodicosapent
Nicodicosapent is a fatty acid niacin conjugate that is also an inhibitor of the sterol regulatory element binding protein (SREBP), a key regulator of cholesterol metabolism proteins such as PCSK9, HMG-CoA reductase, ATP citrate lyase, and NPC1L1.
-
GC17318
Orlistat
Ro 18-0647/002, (-)-Tetrahydrolipstatin
Orlistat is an irreversible inhibitor of lipases in the pancreas and stomach. -
GN10392
Praeruptorin B
-
GC38839
Pseudoprotodioscin
Pseudoprotodioscin, a furostanoside, inhibits SREBP1/2 and microRNA 33a/b levels and reduces the gene expression regarding the synthesis of cholesterol and triglycerides.
-
GC38710
TVB-3166
A FASN inhibitor
-
GC15091
UCM05
G28UCM
fatty acid synthase inhibitor